Effects of low-dose cisplatin on 89Sr therapy for painful bone metastases from prostate cancer: a randomized clinical trial.

No abstract is available for this paper.

• Publication year

  2002

• Venue

  Journal of Nuclear Medicine

• Publication date

  Unknown publication date

• Fields of study

  Medicine

• Identifiers
  PMID 11801708
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• 89Sr radionuclide therapy: Dosimetry and haematological toxicity in two patients with metastasising prostatic carcinoma

  2004cited by this paper
• Radionuclides for metastatic bone pain palliation: a need for rational re-evaluation in the new millennium.

  2000cited by this paper
• Short- and long-term effects of 186Re-1,1-hydroxyethylidene diphosphonate in the treatment of painful bone metastases.

  2000cited by this paper
• Management of cancer pain.

  1999cited by this paper
• Combination 186Re-HEDP and cisplatin supra-additive treatment effects in prostate cancer cells.

  1999cited by this paper
• Prognostic significance of extent of disease in bone in patients with androgen-independent prostate cancer.

  1999cited by this paper
• Platinum compounds as radiosensitizers in strontium-89 metabolic radiotherapy.

  1998cited by this paper
• Unsealed source therapy of painful bone metastases: an update.

  1997cited by this paper
• Radiosensitizing effect of cisplatin in prostate cancer cell lines.

  1996cited by this paper
• Radiosensitization with low-dose carboplatin enhances pain palliation in radioisotope therapy with strontium-89.

  1996cited by this paper
• Strontium 89 therapy for the palliation of pain due to osseous metastases.

  1995cited by this paper
• Platinum drug delivery and radiation for locally advanced prostate cancer.

  1994cited by this paper
• Pain management in the patient with prostate cancer.

  1993cited by this paper
• Pain management in the patient with prostate cancer

  1993cited by this paper
• Strontium-89 (Metastron) versus external beam radiotherapy in patients with painful bone metastases secondary to prostatic cancer: preliminary report of a multicenter trial. UK Metastron Investigators Group.

  1993cited by this paper
• Strontium-89 and low-dose infusion cisplatin for patients with hormone refractory prostate carcinoma metastatic to bone: a preliminary report.

  1992cited by this paper
• Strontium-89 chloride for pain palliation in prostatic skeletal malignancy.

  1991cited by this paper
• Cisplatin and radiation: interaction probabilities and therapeutic possibilities.

  1990cited by this paper
• Radiobiological aspects of low dose rates in radioimmunotherapy.

  1990cited by this paper
• Biologic and clinical developments of cisplatin combined with radiation: concepts, utility, projections for new trials, and the emergence of carboplatin.

  1989cited by this paper
• Half body radiotherapy.

  1989cited by this paper
• Ifosfamide in the treatment of non-small cell lung cancer.

  1989cited by this paper
• Palliation of multiple bone metastases from prostatic carcinoma with strontium-89.

  1988cited by this paper
• Chemotherapy for prostate carcinoma.

  1988cited by this paper
• Important prognostic value of standardized objective criteria of response in stage D2 prostatic carcinoma.

  1988cited by this paper
• Strontium-89 therapy: measurement of absorbed dose to skeletal metastases.

  1988cited by this paper
• Stratification of patients with metastatic prostate cancer based on extent of disease on initial bone scan

  1988cited by this paper
• Combined treatment of radiation and cisdiamminedichloroplatinum (II): a review of experimental and clinical data.

  1987cited by this paper
• Sr-89 therapy for metastatic bone disease: scintigraphic and radiographic follow-up.

  1987cited by this paper
• Treatment of metastatic bone pain with strontium-89.

  1987cited by this paper
• Platinum based combined modality approach for locally advanced head and neck carcinoma.

  1985cited by this paper
• Strontium-89 therapy for the pain of osseous metastases.

  1985cited by this paper
• Modification of the effects of continuous low dose rate irradiation by concurrent chemotherapy infusion.

  1984cited by this paper
• Tumor Concentration of Platinum in Patients with Head and Neck Cancer

  1983cited by this paper
• Pain in far-advanced cancer

  1982cited by this paper
• Human central nervous system distribution of cis-diamminedichloroplatinum and use as a radiosensitizer in malignant brain tumors.

  1982cited by this paper
• Half body radiotherapy

  1976cited by this paper

• Pharmacological Enhancement of Radionuclide Therapy Using Radiopharmaceutical-Drug Combinations in Oncology.

  2025cites this paper
• Platinum group metals for nuclear medicine, a luxurious dream or the future of imaging and therapy: a review

  2025cites this paper
• Real-world progression in the survival of de novo Metastatic prostate cancer over the past decade.

  2023cites this paper
• Evaluations of Anticancer Effects of Combinations of Cisplatin and Tirucallane‐Type Triterpenes Isolated from Amphipterygium adstringens (Schltdl).

  2023cites this paper
• Optimized Therapeutic 177Lu-Labeled PSMA-Targeted Ligands with Improved Pharmacokinetic Characteristics for Prostate Cancer

  2022cites this paper
• The effect of cisplatin-low-level laser therapy on cell viability and death of LNCaP prostate cancer cell line

  2021cites this paper
• Combination radionuclide therapy: A new paradigm.

  2021cites this paper
• Combination Therapy, a Promising Approach to Enhance the Efficacy of Radionuclide and Targeted Radionuclide Therapy of Prostate and Breast Cancer

  2021influential citation
• Preclinical evaluation of platinum-loaded hydroxyapatite nanoparticles in an embryonic zebrafish xenograft model.

  2020cites this paper
• Spine and Non-spine Bone Metastases - Current Controversies and Future Direction.

  2020cites this paper
• Molecular mechanisms and clinical management of cancer bone metastasis

  2020cites this paper
• Radiopharmaceutiques à visée thérapeutique : indications, précautions d’emploi et principaux résultats

  2019cites this paper
• Production of 47Sc, 67Cu, 68Ga, 105Rh, 177Lu, and 188Re using electron linear accelerator

  2019cites this paper
• Bone‐Targeting Radiopharmaceuticals as Monotherapy or Combined With Chemotherapy in Patients With Castration‐Resistant Prostate Cancer Metastatic to Bone

  2019cites this paper
• Nuklearmedizinische Schmerztherapie bei Knochen- und Gelenkerkrankungen

  2019cites this paper
• Targeted Radionuclide Therapy of Painful Bone Metastases: Past Developments, Current Status, Recent Advances and Future Directions.

  2019cites this paper
• Radiotherapy of Skeletal Metastases

  2018cites this paper
• Chapter 4 Radionuclide Pain Palliation Treatment and Radiosynovectomy Elgin Özkan

  2018cites this paper
• Targeted Alpha Therapy, an Emerging Class of Cancer Agents: A Review

  2018cites this paper
• Palliation and Benign Conditions

  2018cites this paper
• Randomized phase III trial to evaluate radiopharmaceuticals and zoledronic acid in the palliation of osteoblastic metastases from lung, breast, and prostate cancer: report of the NRG Oncology RTOG 0517 trial

  2018cites this paper
• Efficacy and safety of 153Sm-EDTMP as treatment of painful bone metastasis: a large single-center study

  2018cites this paper
• Radionuclide Pain Palliation Treatment and Radiosynovectomy

  2017cites this paper
• Radionuclide therapy of malignant bone lesions

  2017cites this paper
• Phase I/II trials of (186)Re-HEDP in metastatic castration-resistant prostate cancer: post-hoc analysis of the impact of administered activity and dosimetry on survival (186)Re-HEDP in

  2017cites this paper
• Palliative Radiotherapy for Bone Metastasis

  2017cites this paper
• Bone-Seeking Radionuclide for Therapy

  2017cites this paper
• Radium-223: Insight and Perspectives in Bone-metastatic Castration-resistant Prostate Cancer.

  2016cites this paper
• Bremsstrahlung dosimetric parameters of beta-emitting therapeutic radionuclides

  2016cites this paper
• Targeted Radionuclide Therapy for Bone Metastasis

  2016cites this paper
• Therapeutic Radiopharmaceuticals for Bone Pain Palliation

  2016cites this paper
• Radium-223 dichloride in clinical practice: a review

  2016cites this paper
• Phase I/II trials of 186Re-HEDP in metastatic castration-resistant prostate cancer: post-hoc analysis of the impact of administered activity and dosimetry on survival

  2016cites this paper
• From palliative therapy to prolongation of survival: 223RaCl2 in the treatment of bone metastases

  2016cites this paper
• Anti-tumour activity of platinum compounds in advanced prostate cancer-a systematic literature review.

  2016cites this paper
• Prostatakarzinom: Palliative Therapie

  2016cites this paper
• Targeting the Cystine/Glutamate Antiporter System xc⁻ in Cancer-Induced Bone Pain

  2015cites this paper
• Metabolism and pharmacokinetics of radium-223 in prostate cancer

  2015cites this paper
• Repression of metadherin inhibits biological behavior of prostate cancer cells and enhances their sensitivity to cisplatin

  2015cites this paper
• Radionuclide therapy for osseous metastases in prostate cancer.

  2015cites this paper
• Use of Animal Models in Understanding Cancer-induced Bone Pain

  2015cites this paper
• Significant toxicities after single fraction HBI include ‘ acute radiation syndrome ’ characterized by severe nausea and vomiting , fever , tachycardia and hypotension

  2015influential citation
• The role of radiation therapy in the treatment of metastatic castrate-resistant prostate cancer

  2015influential citation
• Effects of low-dose capecitabine on Samarium-153-EDTMP therapy for painful bone metastases

  2015cites this paper
• Palliative effects and adverse events of strontium-89 for prostate cancer patients with bone metastasis.

  2015cites this paper
• New radiopharmaceutical agents for the treatment of castration-resistant prostate cancer.

  2015cites this paper
• 177Lu-EDTMP for Treatment of Bone Pain in Patients with Disseminated Skeletal Metastases

  2014cites this paper
• Palliative treatment of bone metastases with samarium-153 EDTMP at onset of pain

  2014cites this paper
• Bone-Seeking Targeted Radio-Nuclide Therapy BT-RNT) in Management of Metastatic Castration-Resistant Prostate Cancer (mCRPC): Shifting fromPalliation to Improving Survival

  2014cites this paper
• Radionuklide in der Therapie von Knochenmetastasen

  2014cites this paper
• 177Lu-EDTMP for palliation of pain from bone metastases in patients with prostate and breast cancer: a phase II study

  2014cites this paper
• Effectiveness of isotope therapy in addition to external beam irradiation therapy for pain control due to bone metastases:―case reports―

  2014cites this paper
• The Radiopharmaceutical Therapy for Multiple Bone Metastases of Cancer

  2014cites this paper
• How are palliative care cancer populations characterized in randomized controlled trials? A literature review.

  2014cites this paper
• Basis of Therapeutic Nuclear Medicine

  2014cites this paper
• Practical guide to the use of radium 223 dichloride.

  2014cites this paper
• Schmerztherapie von Skelettmetastasen mittels ionisierender Strahlung

  2013cites this paper
• Radium-223 for the treatment of prostate cancer

  2013cites this paper
• Le traitement des métastases osseuses par radiopharmaceutiques à tropisme osseux

  2013cites this paper
• [Radiotherapy of skeletal metastases].

  2013cites this paper
• Radium-223 chloride: a potential new treatment for castration-resistant prostate cancer patients with metastatic bone disease

  2013cites this paper
• [Bone metastases treated with radiopharmaceuticals].

  2013cites this paper
• Pathobiology and management of prostate cancer-induced bone pain: recent insights and future treatments

  2013cites this paper
• Targeted Therapy for Bone Metastasis

  2013cites this paper
• Radionuclide Therapy of Bone Metastases

  2013cites this paper
• Impact of ¹⁸F-fluoride PET-CT on implementing early treatment of painful bone metastases with Sm-153 EDTMP.

  2013cites this paper
• Targeted radio-nuclide therapy of skeletal metastases.

  2013cites this paper
• Bone-Targeting Radiopharmaceuticals Including Radium-223

  2013cites this paper
• Clinical Management of Elderly Patients’ Metastatic Prostate Cancer: Other Treatments and Supportive Care

  2013cites this paper
• Bone-targeting radiopharmaceuticals for the treatment of prostate cancer with bone metastases.

  2012cites this paper
• Concurrent use of Sr-89 chloride with zoledronic acid is safe and effective for breast cancer patients with painful bone metastases.

  2012cites this paper
• Radionuclide Therapy of Bone Metastases

  2012cites this paper
• Radiolabelled Bisphosphonates for Bone Pain Palliation

  2012cites this paper
• Chemotherapy Combined with Radionuclide Therapy

  2012cites this paper
• Radiopharmaceuticals for Bone Metastasis Therapy and Beyond: A Voyage from the Past to the Present and a Look to the Future

  2012cites this paper
• Novel therapeutics for the management of castration‐resistant prostate cancer (CRPC)

  2012cites this paper
• Molecular radiotherapy.

  2012cites this paper
• Anti-Tumour Treatment Targeted radionuclide therapy of skeletal metastases

  2012cites this paper
• The role of bone-seeking radionuclides in the palliative treatment of patients with painful osteoblastic skeletal metastases.

  2012cites this paper
• EORTC QLQ-BM22 and QLQ-C30 quality of life scores in patients with painful bone metastases of prostate cancer treated with strontium-89 radionuclide therapy

  2012cites this paper
• Current and emerging treatments in the management of castration-resistant prostate cancer

  2012cites this paper
• Effective use of strontium-89 in osseous metastases

  2012cites this paper
• Targeted "bone-seeking" radiopharmaceuticals for palliative treatment of bone metastases: a systematic review and meta-analysis.

  2012cites this paper
• Pathologies de la prostate : actualités en médecine nucléaire (diagnostic et thérapeutique)

  2011cites this paper
• Bone Seeking Radiopharmaceuticals for Metastatic Bone Pain

  2011cites this paper
• Radionuclide therapy and integrated protocols for bone metastases.

  2011cites this paper
• Internal radiotherapy of painful bone metastases.

  2011cites this paper
• Palliation and Benign Conditions

  2010cites this paper
• Metastasiertes Prostatakarzinom und palliative Maßnahmen

  2010cites this paper
• Multimodality therapy: bone-targeted radioisotope therapy of prostate cancer.

  2010cites this paper
• Samarium-153 treatment of bone pain in patients with metastatic prostate cancer.

  2010cites this paper
• Handbook of Cancer-Related Bone Disease

  2010cites this paper
• Bone-targeted therapy in metastatic prostate cancer: osteoclast inhibitors and bone-seeking radiopharmaceuticals

  2010cites this paper
• Targeted radiotherapy of bone malignancies.

  2010cites this paper
• Radiopharmaceuticals for pain palliation therapy in patients with skeletal metastases, and their possible integration with chemotherapy

  2010cites this paper
• Oncologic Therapy in Cancer Pain

  2010cites this paper
• Metastatic Prostate Cancer

  2010cites this paper
• Hypocalcemia associated with strontium-89 administration in a patient with diffuse bone metastases from neuroendocrine carcinoma.

  2009cites this paper
• Chapter 86. Radiotherapy of Skeletal Metastases

  2009cites this paper
• Can response to palliative treatment with radiopharmaceuticals be further enhanced?

  2009cites this paper